LB Pharmaceuticals Inc
LBRX
$29.66
-$1.75-5.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 49.57% | 76.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 69.65% | 147.24% | |||
| Operating Income | -69.65% | -147.24% | |||
| Income Before Tax | -66.11% | -222.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -66.09% | -222.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -66.09% | -222.61% | |||
| EBIT | -69.65% | -147.24% | |||
| EBITDA | -70.14% | -149.47% | |||
| EPS Basic | -49.44% | 26.27% | |||
| Normalized Basic EPS | -61.28% | 32.04% | |||
| EPS Diluted | -49.44% | 26.27% | |||
| Normalized Diluted EPS | -61.28% | 32.04% | |||
| Average Basic Shares Outstanding | 11.16% | 337.52% | |||
| Average Diluted Shares Outstanding | 11.16% | 337.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||